| Age in years, median (IQR) |
2.8 (0.7–7.1) |
3.4 (1.3–7.0) |
0.097 |
| Males, N (%) |
137 (56) |
140 (56) |
0.966 |
| Deaths, N (%) |
21 (9) |
43 (17) |
0.005 |
| Complicated course, N (%) |
53 (22) |
80 (32) |
0.016 |
| PRISM score, median (IQR) |
11 (7–18) |
15 (10–22) |
<0.001 |
| Mean days to death ± SD |
5.4±6.8 |
5.4±5.7 |
0.955 |
| Median days to death (IQR) |
3 (1–17) |
4 (1–12) |
0.553 |
| PERSEVERE-based mortality probability, mean(95% C.I.) |
9.8 (7.9–11.7) |
12.7 (10.6–14.8) |
0.090 |
| Maximum number of organ failures, median (IQR) |
2 (1–3) |
2 (2–3) |
0.025 |
| Gram-positive bacteria, N (%) |
60 (25) |
58 (23) |
0.759 |
| Number of vasoactive agents at the time ofcorticosteroid initiation, median (IQR) |
– |
2 (1–2) |
– |
| Maximum number of simultaneous vasoactive agentsduring the first 7 days, median (IQR) |
1 (1–2) |
2 (1–3) |
<0.001 |
| Gram-negative bacteria, N (%) |
45 (18) |
58 (23) |
0.252 |
| Other organism, N (%) |
19 (8) |
25 (10) |
0.525 |
| Negative cultures, N (%) |
120 (49) |
111 (44) |
0.291 |
| Comorbidity, N (%) |
70 (29) |
105 (42) |
0.003 |
